Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Study connect Webseite durchsuchen

Recruiting

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia - CC-96191-AML-001

Aktualisiert: 21 Mai, 2024   |   ClinicalTrials.gov

Celgene ist eine reine Tochtergesellschaft von Bristol-Myers Squibb

SIND SIE AN DIESER STUDIE INTERESSIERT?
Drucken Sie diese Seite und den Leitfaden zu klinischen Studien aus, damit Sie sie mit Ihrem Arzt besprechen können.
Nutzen Sie unseren Leitfaden zu klinischen Studien, um mehr über die Schritte für die Teilnahme zu erfahren. Informieren Sie sich über die wichtigsten Punkte, über die Sie nachdenken sollten, und die Fragen, die Sie dem Studienteam stellen sollten, bevor Sie sich für eine Teilnahme entscheiden.

Studiendetails

  • Phase 1

    Phase

  • Geschlecht(er)

  • 18+

    Altersgruppe

  • 10

    Standort(e)

  • Recruiting

Behandlungsmöglichkeiten

Studienarme
ZUGEWIESENE BEHANDLUNG
Experimental: CC-96191
Drug: CC-96191

Wichtigste Eignungskriterien

Inclusion Criteria: Participants must satisfy the following criteria to be enrolled in the study: 1. Participant must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessments/procedures being conducted. 3. Participant is ≥ 18 years of age at the time of signing the ICF. 4. Relapsed or refractory CD33 positive AML at last visit as defined by the World Health Organization (WHO) Classification who have failed or who are ineligible for or have refused all available therapies for AML which may provide clinical benefit. 6. Participant has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2. 7. At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion without conditioning. 8. Participants must have adequate hematologic, liver, renal, and coagulation function as assessed by laboratory tests 9. Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and during the safety follow-up period. Exclusion Criteria: The presence of any of the following will exclude a Participant from enrollment: 1. Participant is suspected or proven to have acute promyelocytic leukemia (FAB M3) based on morphology, immunophenotype, molecular assay, or karyotype. 2. Participant has received systemic anticancer therapy (including investigational therapy) or radiotherapy < 28 days or 5 half-lives, whichever is shorter, prior to the start of study treatment. Hydroxyurea is allowed to control peripheral leukemia blasts. 3. Participants with prior autologous hematopoietic stem cell transplant who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (eg, transplant-related side effects). 4. Prior allogeneic HSCT with either standard or reduced intensity conditioning ≤ 6 months prior to dosing. 5. Participants on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of topical steroids for ongoing skin or ocular GVHD is permitted. 6. Participant has persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to < Grade 2. 7. Participant has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening. 8. History of concurrent second cancers requiring active, ongoing systemic treatment. 9. Participant is known seropositive or active infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus or hepatitis C virus. 10. Impaired cardiac function or clinically significant cardiac diseases, as defined in the protocol . 11. Participant is a pregnant or lactating female.

Wir empfehlen Ihnen dringend, sich an Bristol Myers Squibb zu wenden, um Nebenwirkungen (unerwünschte Ereignisse) zu melden.
Nebenwirkungen (unerwünschte Ereignisse) und andere meldepflichtige Ereignisse werden hier definiert
Nebenwirkungen (unerwünschte Ereignisse) oder Produktqualitätsbeschwerden melden: Medizinische Information